Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 38, 2003 - Issue 6
Submit an article Journal homepage
23
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Effect of Antiviral Therapy on Markers of Fibrogenesis in Patients with Chronic Hepatitis C

Nøjgaard C. Dept. of Gastroenterology H:S, Hvidovre Hospital University of Copenhagen Denmark
,
Johansen J. S. Dept. of Clinical Physiology and Nuclear Medicine H:S, Hvidovre Hospital University of Copenhagen Denmark
,
Krarup H. B. Dept. of Clinical Biochemistry Aalborg Hospital Denmark
,
Holten-Andersen M. The Finsen Laboratory, Rigshospitalet University of Copenhagen Denmark
,
Møller, A. Dept. of Medicine Kolding Sygehus Denmark
&
Bendtsen and the Danish Viral Hepatitis Study Group F. Dept. of Gastroenterology H:S, Hvidovre Hospital University of Copenhagen Denmark
Pages 659-665 | Published online: 08 Jul 2009

  • Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32 Suppl 1:98-112.
  • McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998:339:1485-92.
  • Reichard O, Norkrans G, Frydén A, Braconier J-H, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon 2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
  • Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997:26:961-6.
  • Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998:352:1426-32.
  • Chemello L, Cavalletto L, Casarin C, Bonetti P, Bemardinello E, Pontisso P, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-á in chronic hepatitis C. Ann Intern Med 1996:124:1058-60.
  • Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994;39: 977-82.
  • Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26 Suppl 1:122-78.
  • Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Härter D, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998:28:1687-95.
  • Manns M, McHutchison JG, Gordon SC, Rustgi VK, Shiftman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001:22358:958-65.
  • Torres-Saunas M, Pères A, Caballerfa J, Jiménez W, Heredia D, Bruguera M, et al. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. Gastroenterology 1986;90:1241-6.
  • Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJT. Gp38k, a protein synthesized by vascular smooth muscle cells stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-73.
  • Shackelton LM, Mann DM, Millis AJT. Identification of a 38kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995; 270: 13076-83.
  • De Ceuninck F, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (Cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun 2001;285:926-31.
  • Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase Bmediated signalling pathways. Biochem J 2002;365:119-26.
  • Bentsen KD, Horn T, Risteli J, Risteli L, Engström-Laurent A, Hørslev-Petersen K, et al. Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse. Liver 1987;7:339-46.
  • Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34: 715-8.
  • Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Longterm decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995;22:426-31.
  • Walsh K, Fletcher A, MacSween RNM, Morris AJ. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. Eur J Gastroenterol Hepatol 1999; 11: 827-31.
  • Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. J Hepatol 1997:26:574-83.
  • Lichtinghagen R, Huegel O, Seifert T, Haberkom CI, Michels D, Flemming P, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000;46:183-92.
  • Friedman SL. The cellular basis of hepatic fibrosis. N Engl J Med 1993:328:1828-35.
  • Mathew J, Geerts A, Burts AD. Pathobiology of hepatic stellate cells. Hepato-Gastroenterol 1996;43:72-91.
  • Johansen JS, Christoffersen P, Mø11er S, Price PA, Henriksen JH, Garbarsch C, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-20.
  • Johansen JS, Mø11er S, Price PA, Bendtsen F, Junge J, Garbarsch C, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32: 582-90.
  • Tran A, Benzaken S, Saint-Paul M-C, Guzman-Granier E, Hastier P, Pradier C, et al. Chondrex (YKL-40), a potential new serum flbrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000;12:989-93.
  • Walsh KM, Timms P, Campbell S, Maclver MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-I and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C. Dig Dis Sei 1999;44:624-30.
  • Murawaki Y, IKuta Y, Idobe Y, Kitamura Y, Kawasaki H. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997;26:1213-9.
  • Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease. J Hepatol 1999;30: 1090-8.
  • Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheum 1996;35:553-9.
  • Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495-503.
  • Kramp HB, Drewes AM, Madsen PH. A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 1998;58: 415-22.
  • Harvey S, Weisman M, O'Dell J, Scott T, Krusemeier M, Visor J, et al. Chondrex: new marker of joint disease. Clin Chem 1998; 44:509-16.
  • Mitsuda A, Suou T, Ikuta Y, Kawasaki H. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. J Hepatol 2000;32:66672.
  • Nunes DP, Offner GD, Keaveny A, Maldanado N, O'Brien M, Wilson S, et al. Comparative study of YKL-40 (Chondrex), procollagen III peptide and hyaluronan for the diagnosis of hepatitis C associated liver flbrosis [abstract]. Hepatology 1998; 28:408 A.
  • Mallat A, Preaux A-M, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995:21:1003-10.
  • Zhou Y, Wang S, Gobi A, öberg K. The interferon-a regulation of interferon regulatory factor 1 (IRF-I) and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol 2000; 11:707-14.
  • Dufour J-F, DeLellis R, Kaplan MM. Regression of hepatic flbrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998:43:2573-6.
  • Hollen-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000;6:4292-9.
  • Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999;31 Suppl 1:61-4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.